MedPath

Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management

Not Applicable
Completed
Conditions
Diabetes (Insulin-requiring, Type 1 or Type 2)
Registration Number
NCT00922376
Lead Sponsor
University College London Hospitals
Brief Summary

New telemedicine systems have been designed to assist people suffering from diabetes in the management of their chronic disease. More recently the focus has been moving to portable systems equipped with Bluetooth. This study consists of evaluating an application called the Think Positive (T+) diabetes management software. It is a randomized controlled trial designed to compare, over a nine month period, a group of patients receiving usual care with a group of patients using the T+ system. The objectives of the study are to investigate the extent to which this telemedicine application helps patients control their blood sugar levels (HbA1c), as well as the extent to which its users consider it to be acceptable. The impact of its use on factors such as diabetes self-care, health status, quality of life, self-confidence in diabetes management, fear of hypoglycemia and illness representations will also be examined. Because of the supplementary real-time support and feedback that T+ offers, its use should lead to better outcomes in diabetes management than usual care does.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
86
Inclusion Criteria
  • Type 1 and type 2 diabetes patients
  • Insulin requiring patients
  • Sufficiently fluent in english
  • HbA1c > 7.5
  • Last visit with Diabetes Specialist Nurse (DSN) < 12 months
Exclusion Criteria
  • Psychiatric disorders
  • Poor vision or/and lack of manual dexterity
  • Prior use of T+
  • Participation in another ongoing trial
  • Patients with antenatal/gestational
  • Patients who are in transition between the children services and adult services Insulin pump users

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Blood sugar levels (HbA1c)Baseline, 3 months, 9 months
Secondary Outcome Measures
NameTimeMethod
BMIBaseline, 3 months, 9 months
Number of Hypoglycemic eventsBaseline, 3 months, 9 months
Blood pressureBaseline, 3 months, 9 months
Diabetes self-careBaseline, 3 months, 9 months
Diabetes self- efficacyBaseline, 3 months, 9 months
Quality of lifeBaseline, 3 months, 9 months
Health statusBaseline, 3 months, 9 months
Illness representationsBaseline, 3 months, 9 months
User acceptability of T+3 months, 9 months
Nurses' Perceptions of T+Baseline, 3 months, 9 months
Self efficacy in using T+3 months, 9 months
Health care utilizationbaseline, 3 months, 9 months
Self managementbaseline, 3 months, 9 months

2 subscales of the HeiQ questionnaire.

Trial Locations

Locations (1)

University College London (UCL)

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath